101 related articles for article (PubMed ID: 7528030)
1. Treatment of unresectable hepatocellular carcinoma with a combination of human recombinant alpha-2b interferon and doxorubicin: results of a pilot study.
Lotz JP; Grange JD; Hannoun L; Boudghene F; Amiot X; Lamarque D; Andre T; Esteso A; Bellaiche A; Bouleuc C
Eur J Cancer; 1994; 30A(9):1319-25. PubMed ID: 7528030
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of recombinant leukocyte A interferon (IFN-alpha 2A, Roferon-A) with doxorubicin in advanced malignant disease.
Creagan ET; Frytak S; Long HJ; Kvols LK
Cancer; 1989 Sep; 64(5):1034-7. PubMed ID: 2474365
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
Yeo W; Mok TS; Zee B; Leung TW; Lai PB; Lau WY; Koh J; Mo FK; Yu SC; Chan AT; Hui P; Ma B; Lam KC; Ho WM; Wong HT; Tang A; Johnson PJ
J Natl Cancer Inst; 2005 Oct; 97(20):1532-8. PubMed ID: 16234567
[TBL] [Abstract][Full Text] [Related]
4. Hepatic intra-arterial interferon alpha 2b-based immunotherapy combined with 5-fluorouracil (5-FU)-based systemic chemotherapy for patients with hepatocellular carcinoma (HCC) not responsive and/or not eligible for conventional treatments: a pilot study.
Vitale FV; Romeo P; Vasta F; Panebianco V; Calì S; Rotondo S; Ferraù F; La Greca M
Anticancer Res; 2007; 27(6B):4077-81. PubMed ID: 18225574
[TBL] [Abstract][Full Text] [Related]
5. No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma.
Bokemeyer C; Kynast B; Harstrick A; Laage E; Schmoll E; von Wussow P; Schmoll HJ
Cancer Chemother Pharmacol; 1995; 35(4):334-8. PubMed ID: 7828277
[TBL] [Abstract][Full Text] [Related]
6. Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b.
Patt YZ; Yoffe B; Charnsangavej C; Pazdur R; Fischer H; Cleary K; Roh M; Smith R; Noonan CA; Levin B
Cancer; 1993 Nov; 72(9):2574-82. PubMed ID: 7691392
[TBL] [Abstract][Full Text] [Related]
7. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
Leung TW; Tang AM; Zee B; Yu SC; Lai PB; Lau WY; Johnson PJ
Cancer; 2002 Jan; 94(2):421-7. PubMed ID: 11905412
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
[TBL] [Abstract][Full Text] [Related]
9. Combination of cisplatin and interferon-alpha 2a (Roferon-A) in patients with non-small cell lung cancer (NSCLC). An open phase II multicentre study.
Kataja V; Yap A
Eur J Cancer; 1995; 31A(1):35-40. PubMed ID: 7695976
[TBL] [Abstract][Full Text] [Related]
10. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
12. [Prolonged partial remission of a hepatocellular carcinoma treated with adriamycin and recombinant human alpha-2 interferon].
Amiot X; Grangé JD; Boudghene F; Lamarque D; Lotz JP; Izrael V; Bodin F
Ann Gastroenterol Hepatol (Paris); 1991 Oct; 27(5):211-4. PubMed ID: 1660687
[TBL] [Abstract][Full Text] [Related]
13. A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma.
Ang MK; Poon D; Foo KF; Chung YF; Chow P; Wan WK; Thng CH; Ooi L
Hematol Oncol Stem Cell Ther; 2008; 1(3):159-65. PubMed ID: 20063546
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of combined alpha interferon, alpha difluoromethylornithine (DFMO), and doxorubicin in advanced malignancy.
Ganju V; Edmonson JH; Buckner JC
Invest New Drugs; 1994; 12(1):25-7. PubMed ID: 7960601
[TBL] [Abstract][Full Text] [Related]
15. Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma.
Kardinal CG; Moertel CG; Wieand HS; Schutt AJ; O'Connell MJ; Wright K; Wiesenfeld M; Tschetter LK; Krook JE
Cancer; 1993 Apr; 71(7):2187-90. PubMed ID: 8384064
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma.
Colleoni M; Buzzoni R; Bajetta E; Bochicchio AM; Bartoli C; Audisio R; Bonfanti G; Nolè F
Cancer; 1993 Dec; 72(11):3196-201. PubMed ID: 8242542
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma.
Feun LG; Savaraj N; Hung S; Reddy R; Jeffers L; Benedetto P; Livingstone AS; Ardalan B; Levi JU; Parker T
Am J Clin Oncol; 1994 Oct; 17(5):393-5. PubMed ID: 8092109
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer.
Patt YZ; Hassan MM; Lozano RD; Waugh KA; Hoque AM; Frome AI; Lahoti S; Ellis L; Vauthey JN; Curley SA; Schnirer II; Raijman I
Clin Cancer Res; 2001 Nov; 7(11):3375-80. PubMed ID: 11705850
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin.
Schiller JH; Hawkins MJ; O'Connell MJ; Sielaff K; Borden EC
J Biol Response Mod; 1989 Jun; 8(3):252-61. PubMed ID: 2746297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
